Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2017) 49 EP71 | DOI: 10.1530/endoabs.49.EP71

1Department of Endocrinology, University Hospital Center Zagreb, Zagreb, Croatia; 2Department of Urology, University Hospital Center Zagreb, Zagreb, Croatia.


The role of systemic inflammation in promoting tumor progression has been a topic of increasing interest. Neutrophil-lymphocyte ratio (NLR) >5 and platelet-lymphocyte ratio (PLR) >190 used as indicators of inflammation have been reported to have prognostic value in numerous solid tumors. The aim of this retrospective study was to investigate NLR and PLR as biomarkers in distinguishing between adrenocortical adenomas and adrenocortical carcinomas (ACC). Nineteen patients with ACC (mean age 54 years, range 24–75; eight male, 11 female) and 22 patients with adrenal adenomas (mean age 47 years, range 28–71; six male, 16 female) were enrolled in the study. In the ACC group, only one patient presented with functional tumor (excess estradiol), whereas all the others were discovered incidentally. Eleven out of 19 patients with ACC were operated laparoscopically, while the open approach was used in eight of them. In the adenoma group, the first presentation of the disease was hyperandrogenemia in one patient, and in the rest of the group, adenoma was discovered incidentally. Open surgical approach was used in one patient with adenoma and the others were operated laparoscopically. The mean size of adenoma was 5.8 cm while the mean ACC size was 9 cm (P<0.05). In the ACC group, NLR>5 was found in 26.3% (5/19) patients which was higher compared to 9% (2/22) of the patients with NLR>5 in the adenoma group. PLR>190 was found in 36.8% (7/19) of ACC patients compared to 18.2% (4/22) in the adenoma group. Mean NLRs in the ACC and in the adenoma group were 3.6 and 3.1, respectively (P=0.886) and mean PLRs were 219.1 and 143.3, respectively (P=0.026). Our results indicate that in addition to tumor size, PLR might potentially serve as biomarker of malignant tumor behavior.

Volume 49

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.